Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the …
UA Matulonis, D Lorusso, A Oaknin… - Journal of clinical …, 2023 - ascopubs.org
PURPOSE Single-agent chemotherapies have limited activity and considerable toxicity in
patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab …
patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab …
Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR …
Ł Biegała, A Gajek, A Marczak, A Rogalska - Cells, 2023 - mdpi.com
The PARP inhibitor (PARPi) olaparib is currently the drug of choice for serous ovarian
cancer (OC), especially in patients with homologous recombination (HR) repair deficiency …
cancer (OC), especially in patients with homologous recombination (HR) repair deficiency …
[HTML][HTML] BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges
L Collet, B Hanvic, M Turinetto, I Treilleux… - Frontiers in …, 2024 - frontiersin.org
BRCA1/2 genes are part of homologous recombination (HR) DNA repair pathways in charge
of error-free double-strand break (DSB) repair. Loss-of-function mutations of BRCA1/2 …
of error-free double-strand break (DSB) repair. Loss-of-function mutations of BRCA1/2 …
[HTML][HTML] Ovarian cancer recurrence: Is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments?: A clinical perspective
PG Rose - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
In view of the high risk of recurrent disease in stage III and IV ovarian cancer following
primary first-line chemotherapy, a variety of maintenance and consolidation treatment …
primary first-line chemotherapy, a variety of maintenance and consolidation treatment …
OPERA: A phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer
J Park, HW Cho, MC Lim, CH Choi, JY Lee - Future oncology, 2024 - Taylor & Francis
A consensus regarding subsequent therapeutic strategies for patients with platinum-and
poly (ADP-ribose) polymerase inhibitor (PARPi)-resistant ovarian cancer is lacking. These …
poly (ADP-ribose) polymerase inhibitor (PARPi)-resistant ovarian cancer is lacking. These …
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II …
AA Secord, SN Lewin, CG Murphy, SC Cecere… - Annals of …, 2024 - Elsevier
Background Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha
(FRα)-targeting antibody–drug conjugate with United States Food and Drug Administration …
(FRα)-targeting antibody–drug conjugate with United States Food and Drug Administration …
[HTML][HTML] Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer
A Xu-Vuillard, C Guerin-Charbonnel, F Bocquet… - ESMO open, 2024 - Elsevier
Background Poly (ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian
cancer treatment. Most patients progress during or following PARPi exposure, however, with …
cancer treatment. Most patients progress during or following PARPi exposure, however, with …
Efficacy and safety of platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance for recurrent ovarian, fallopian tube, and primary …
M Abe, T Shoji, Y Chiba, E Takatori, Y Kaido… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: In recent years, the usefulness of poly ADP-ribose polymerase (PARP)
inhibitors as subsequent maintenance therapy with poly ADP-ribose polymerase (PARP) …
inhibitors as subsequent maintenance therapy with poly ADP-ribose polymerase (PARP) …
[HTML][HTML] Robotic Rectosigmoid Resection with Totally Intracorporeal Colorectal Anastomosis (TICA) for Recurrent Ovarian Cancer: A Case Series and Description of …
V Gallotta, L Palmieri, F Santullo, C Certelli… - Journal of Personalized …, 2024 - mdpi.com
Background: Most patients with ovarian cancer relapse within 2 years. Prospective
randomized trials, such as DESKTOP III and SOC-I, have shown the role of secondary …
randomized trials, such as DESKTOP III and SOC-I, have shown the role of secondary …
A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line …
HW Cho, HS Kim, JY Park, YY Lee, MC Lim… - International Journal of …, 2024 - Elsevier
Background Although two recent phase III randomized controlled trials showed survival
benefits of undergoing secondary cytoreductive surgery for an initial relapse of ovarian …
benefits of undergoing secondary cytoreductive surgery for an initial relapse of ovarian …